文献速递消化系统肿瘤

微卫星不稳定性作为胃癌生物标志物的个体患者数据荟萃分析

Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.
PubMed 文献 · J Clin Oncol · 2019-09-12

该个体患者数据荟萃分析纳入MAGIC、CLASSIC、ARTIST和ITACA-S四项试验中1556例可切除胃癌患者,评估MSI的预后和预测价值。MSI-high患者5年DFS和OS均显著优于MSI-low/MSS患者,且MSI-low/MSS患者从化疗联合手术中获益,而MSI-high患者未显示获益。

要点

  • MSI-high是可切除胃癌的强预后良好标志,5年DFS 71.8% vs 52.3%,OS 77.5% vs 59.3%。
  • MSI-low/MSS患者从化疗联合手术中显著获益(DFS HR 0.65,OS HR 0.75)。
  • MSI-high患者未从化疗联合手术中获益(DFS HR 1.27,OS HR 1.50),需前瞻性研究豁免化疗或免疫治疗。

核心结论

  • 在可切除原发性胃癌中,MSI是稳健的预后标志物,应作为临床试验的分层因素。
  • MSI-high胃癌患者可能不应接受辅助化疗,而应前瞻性研究免疫检查点阻断。

研究设计与样本

  • 多国个体患者数据荟萃分析,纳入MAGIC、CLASSIC、ARTIST和ITACA-S四项试验。
  • 共1556例可切除胃癌患者,MSI状态可评估,其中121例(7.8%)为MSI-high。
  • 576例欧洲患者,980例亚洲患者。
  • 预后分析采用多变量Cox模型,预测作用通过治疗与MSI交互作用检验。

主要发现

  • MSI-high vs MSI-low/MSS的5年DFS为71.8%(95%CI 63.8%-80.7%)vs 52.3%(95%CI 49.7%-55.1%)。
  • MSI-high vs MSI-low/MSS的5年OS为77.5%(95%CI 70.0%-85.8%)vs 59.3%(95%CI 56.6%-62.1%)。
  • MSI-low/MSS患者化疗联合手术vs单纯手术:5年DFS 57% vs 41%(HR 0.65,95%CI 0.53-0.79),5年OS 62% vs 53%(HR 0.75,95%CI 0.60-0.94)。
  • MSI-high患者化疗联合手术vs单纯手术:5年DFS 70% vs 77%(HR 1.27,95%CI 0.53-3.04),5年OS 75% vs 83%(HR 1.50,95%CI 0.55-4.12)。

关键数值与推荐

  • MSI-high定义为微卫星高度不稳定,MSI-low/MSS为微卫星低度不稳定/稳定。
  • MSI状态可评估患者1556例,MSI-high 121例(7.8%)。
  • 预后分析采用多变量Cox模型,预测作用通过治疗与MSI交互作用检验。

临床怎么用

  • 可切除胃癌应检测MSI状态,用于预后分层和临床试验分层。
  • MSI-low/MSS患者可从化疗联合手术中获益,应推荐辅助化疗。
  • MSI-high患者可能豁免化疗,需前瞻性研究免疫检查点阻断。

局限性

  • MSI-high患病率低(7.8%),样本量有限。
  • MSI-high患者化疗获益的置信区间宽,需前瞻性验证。
  • 研究基于四项试验的回顾性个体患者数据荟萃分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In the CLASSIC and MAGIC trials, microsatellite instability (MSI)-high status was a favorable prognostic and potential negative predictive factor for neoadjuvant/adjuvant chemotherapy in resectable gastric cancer (GC). Given the low prevalence of MSI-high status in GC and its association with other positive prognostic variables, large data sets are needed to draw robust evidence of its prognostic/predictive value. PATIENTS AND METHODS: We performed a multinational, individual-patient-data meta-analysis of the prognostic/predictive role of MSI in patients with resectable GC enrolled in the MAGIC, CLASSIC, ARTIST, and ITACA-S trials. Prognostic analyses used multivariable Cox models (MVM). The predictive role of MSI was assessed both in an all-comer population and in MAGIC and CLASSIC trials by MVM testing of the interaction of treatment (chemotherapy plus surgery v surgery) with MSI. RESULTS: MSI status was available for 1,556 patients: 121 (7.8%) had MSI-high status; 576 were European, and 980 were Asian. In MSI-high versus MSI-low/microsatellite stable (MSS) comparisons, the 5-year disease-free survival (DFS) was 71.8% (95% CI, 63.8% to 80.7%) versus 52.3% (95% CI, 49.7% to 55.1%); the 5-year overall survival (OS) was 77.5% (95% CI, 70.0% to 85.8%) versus 59.3% (95% CI, 56.6% to 62.1%). In MVM, MSI was associated with longer DFS (hazard ratio [HR], 1.88; 95% CI, 1.28 to 2.76; P < .001) and OS (HR, 1.78; 95% CI, 1.17 to 2.73; P = .008), as were pT, pN, ethnicity, and treatment. Patients with MSI-low/MSS GC benefitted from chemotherapy plus surgery: the 5-year DFS compared with surgery only was 57% versus 41% (HR, 0.65; 95% CI, 0.53 to 0.79), and the 5-year OS was 62% versus 53% (HR, 0.75; 95% CI, 0.60 to 0.94). Conversely, those with MSI-high GC did not: the 5-year DFS was 70% versus 77% (HR, 1.27; 95% CI, 0.53 to 3.04), and the 5-year OS was 75% versus 83% (HR, 1.50; 95% CI, 0.55 to 4.12). CONCLUSION: In patients with resectable primary GC, MSI is a robust prognostic marker that should be adopted as a stratification factor by clinical trials. Chemotherapy omission and/or immune checkpoint blockade should be investigated prospectively in MSI-high GCs according to clinically and pathologically defined risk of relapse.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pietrantonio F, Miceli R, Raimondi A, et al. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. J Clin Oncol. 2019. PMID: 31513484. doi:10.1200/JCO.19.01124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。